Nektar Therapeutics (NASDAQ:NKTR) Just Reported And Analysts Have Been Lifting Their Price Targets

Nektar Therapeutics Third Quarter 2024 Earnings: Beats Expectations

Nektar Q3 Loss Narrower Than Expected, Pipeline Development in Focus

Nektar Therapeutics (NKTR) Q3 2024 Earnings Call Highlights: Strategic Moves and Financial Outlook

Nektar Therapeutics (NKTR) Reports Q3 Loss, Tops Revenue Estimates

Nektar: Q3 Earnings Snapshot

Nektar Therapeutics Reports Third Quarter 2024 Financial Results

Nektar and Collaborators Present Late-breaking Results from Phase 2 Study of NKTR-255 for the Treatment of Radiation Induced Lymphopenia in Locally Advanced Non-Small Cell Lung Cancer Patients at Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nektar Therapeutics to Participate in Upcoming Investor Conferences

Nektar Therapeutics to sell Alabama facility to Ampersand

Eczema Drug Developer Nektar Gains Analyst Confidence With 400% Upside Potential

Nektar Announces Definitive Agreement with Ampersand Capital Partners to Sell Its Commercial PEGylation Reagent Manufacturing Business in Alabama